<DOC>
	<DOCNO>NCT01654731</DOCNO>
	<brief_summary>Primary biliary cirrhosis ( PBC ) chronic cholestatic liver disease eventually lead end-stage liver failure death unless liver transplantation ( LT ) perform . Ursodeoxycholic acid ( UDCA ) administer orally daily dose 13-15 mg/kg currently drug approve treatment PBC . UDCA consistently improve biochemical liver test , prolongs survival without LT , delay histological progression well occurrence portal hypertension . However , significant proportion ( 40 % ) patient treat UDCA show incomplete biochemical response remain high risk death LT . The development new treatment combination UDCA therefore need . Several candidate exist among Bezafibrate . Bezafibrate belong fibrates ' pharmacological class , develop 4 decade ago treatment mixed hyperlipidaemia . Bezafibrate cheap , widely available well tolerate . There substantial body circumstantial evidence support fibrates , Bezafibrate particular , well tolerate improve biochemical liver test patient PBC incomplete response UDCA . However , despite several positive successful pilot study , still phase 3 randomized placebo-controlled trial fibrates treatment PBC . The purpose protocol therefore conduct trial select population patient PBC base incomplete biochemical response 6 month UDCA therapy .</brief_summary>
	<brief_title>Phase 3 Study Bezafibrate Combination With Ursodeoxycholic Acid Primary Biliary Cirrhosis</brief_title>
	<detailed_description>This multi-center , randomize ( treatment assign chance ) , placebo-controlled ( inactive substance compare test drug see whether drug real effect ) , parallel-group ( two group patient receive different treatment ) study assess efficacy safety bezafibrate patient primary biliary cirrhosis ( PBC ) inadequate biochemical response ursodeoxycholic acid , define Paris II criterion . Bezafibrate 400 mg placebo daily administer combination ursodeoxycholic acid ( UDCA ) 13-15 mg/kg/d 24 month . Patient safety monitor . Primary end-point percentage patient complete normalization follow biochemical test : alkaline phosphatase , aminotransferase , total bilirubin , serum albumin , prothrombin index . Secondary endpoint include percentage drug-related adverse event , survival rate without liver transplantation liver decompensation , time course non-invasive liver fibrosis measurement ( Fibroscan , serum hyaluronic acid ) , time course liver histological parameter ( fibrosis stage , necro-inflammatory grade , ductopenia ) assess percutaneous biopsy specimen , time course endoscopic , ultrasound , biochemical feature portal hypertension , time course pruritus quality life use validated scale .</detailed_description>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<mesh_term>Bezafibrate</mesh_term>
	<criteria>Age &gt; 18 Patient PBC define 2 3 follow criterion Positive antimitochondrial antibody type M2 . Abnormal serum alkaline phosphatase ( ALP &gt; 1,5N ) aminotransferase ( AST ALT &gt; 1N ) activity . Histological hepatic injury consistent PBC biopsy specimen least 10 mm . Patient treat UDCA dose 13 15 mg/kg/d ( consistent AMM ) Patients show incomplete biochemical response UDCA define : ALP &gt; 1,5N AST &gt; 1,5N total bilirubin &gt; 17 µmol/l ( conjugate bilirubin &gt; 8 µmol/l ) ≥ 3 month UDCA dose 13 15 mg/kg/day . Unsigned consent . Patient social insurance medical assistant state Ascites gastrointestinal bleeding ( history ) Serum total bilirubinemia &gt; 50 μmols/L ( 3 mg/dl ) ( sample &lt; 3 month ) Serum albuminemia &lt; 35 g/l ( sample &lt; 3 month ) Prothrombin index &lt; 70 % ( sample &lt; 3 month ) Platelet count &lt; 100000/mm3 ( sample &lt; 3 month ) Treatment corticosteroid , immunosuppressive agent , fibrates ( PPARagonists ) statin last 3 month Any comorbidity susceptible cause hepatic impairment ( HBV , HCV , HIV seropositivity ; excessive alcohol consumption ; hemochromatosis , Wilson 's disease , α1 antitrypsin deficiency ; celiac disease ; uncontrolled dysthyroidism ; autoimmune hepatitis , inflammatory colitis ) Any severe comorbidity decrease life expectancy Intolerance hypersensitivity fibrates , one component fibrates general Known photosensitivity reaction fibrates Pregnancy desire pregnancy Breastfeeding Renal failure ( clearance creatinine &lt; 60 ml/mn ) Patient congenital galactosemia , syndrome glucose malabsorption , lactase deficiency due presence lactose tablet bezafibrate 400 mg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PBC</keyword>
	<keyword>Bezafibrate</keyword>
</DOC>